Clinical Assessment and Principles of Management of Psoriatic Arthritis

Philip Mease, MD, director of rheumatology research at Swedish Medical Center and clinical professor at the University of Washington School of Medicine in Seattle, discusses key points regarding the diagnosis and treatment of psoriatic arthritis in this video produced by the Cleveland Clinic Center for Continuing education.

Philip Mease, MD, director of rheumatology research at Swedish Medical Center and clinical professor at the University of Washington School of Medicine in Seattle, discusses key points regarding the diagnosis and treatment of psoriatic arthritis in this video produced by the Cleveland Clinic Center for Continuing education.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff - stock.adobe.com
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB - stock.adobe.com
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin - stock.adobe.com
Dermatologist examining the skin of a patient | Image Credit: thodonal - stock.adobe.com
Public Health Matters podcast logo
Smiling Asian female pharmacist working in chemist shop or pharmacy | Image Credit: Atstock Productions - stock.adobe.com
sofiko14 / stock.adobe.com
Mammogram scans | Image credit: okrasiuk - stock.adobe.com
WP_7824 / stock.adobe.com
Related Content

Three Key Services Pharmaceutical Manufacturers Provide Patients: Are You Taking Advantage?

March 30th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

AbbVie’s Upadacitinib Meets Primary Endpoint for Systemic Lupus Erythematosus

March 28th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Risankizumab Meets Primary Endpoint of Clinical Remission for Moderate to Severe Ulcerative Colitis

March 28th 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Three Key Services Pharmaceutical Manufacturers Provide Patients: Are You Taking Advantage?

March 30th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

AbbVie’s Upadacitinib Meets Primary Endpoint for Systemic Lupus Erythematosus

March 28th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Risankizumab Meets Primary Endpoint of Clinical Remission for Moderate to Severe Ulcerative Colitis

March 28th 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Three Key Services Pharmaceutical Manufacturers Provide Patients: Are You Taking Advantage?

March 30th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

AbbVie’s Upadacitinib Meets Primary Endpoint for Systemic Lupus Erythematosus

March 28th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Risankizumab Meets Primary Endpoint of Clinical Remission for Moderate to Severe Ulcerative Colitis

March 28th 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.